Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Melanoma 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 5Biopsy 4pembrolizumab 2olaparib 2durvalumab 2ceralasertib 2Nivolumab 2trastuzumab deruxtecan 1pelcitoclax 1pazopanib 1cobimetinib 1cediranib 1capivasertib 1cabozantinib 1X-Rays 1Taxes 1Radiation 1Phantoms, Imaging 1Paclitaxel 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Fluid Therapy 1Disulfides 1Congresses as Topic 1Carboplatin 1CTLA-4 Antigen 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinosarcoma × cobimetinib × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡